Clinical Trials on AQP4+ NMOSD in Canada

Total 2 results

Hoffmann-La Roche
Chugai Pharmaceutical Co.

Terminated

A Study In Neuromyelitis Optica Spectrum Disorder (NMOSD) With Satralizumab As An Intervention (SAkuraBonsai)

Neuromyelitis Optica Spectrum Disorder | NMOSD

United States, Korea, Republic of, Italy, Canada, Japan, Turkey
Hoffmann-La Roche
Chugai Pharmaceutical

Completed

Efficacy and Safety Study of Satralizumab (SA237) as Monotherapy to Treat Participants With Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD)

Neuromyelitis Optica (NMO) | NMO Spectrum Disorder (NMOSD)

United States, Korea, Republic of, Malaysia, Turkey, Bulgaria, Canada, Poland, Puerto Rico, Romania, Croatia, Georgia, Italy, Philippines, Taiwan, Ukraine

3

Subscribe